Zogenix, Inc. (NASDAQ: ZGNX)

DEFENDANT NAME: Zogenix, Inc.
STOCK SYMBOL: NASDAQ: ZGNX
CASE NUMBER:
CASE NAME:
COURT: U.S. District Court for the Northern District of California
PRACTICE AREA: Investor Fraud
STATUS: Investigation
CLASS PERIOD: Feb. 6, 2019 - Apr. 8, 2019
LEAD PLAINTIFF DEADLINE: June 11, 2019
DATE FILED:
COURT LOCATION:
RELATED DOCUMENTS:
CONTACT:
510-725-3000 ZGNX@hbsslaw.com

FILL OUT THE FORM TO FIND OUT YOUR INVESTOR RIGHTS TO POTENTIAL COMPENSATION »

Hagens Berman Sobol Shapiro LLP reminds investors in Zogenix, Inc. (NASDAQ: ZGNX) of the June 25, 2019 Lead Plaintiff deadline in the securities class action pending in the U.S. District Court for the Northern District of California.

If you purchased or otherwise acquired securities of ZGNX between February 6, 2019 and April 8, 2019 and suffered losses you do not need to sign up to be included in the putative class of investors.  If you suffered losses in excess of $50,000, you may qualify to be a lead plaintiff – one who selects and oversees the attorneys prosecuting the case.  If you wish to serve as a lead plaintiff in this class action contact Hagens Berman Sobol Shapiro LLP.  For more infomation contact Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000 or emailing ZGNX@hbsslaw.com.

According to the complaint, Defendants misled investors about Zogenix’s much-anticipated New Drug Application (“NDA”) for FINTEPLA®.  More specifically, according to the complaint, the NDA (1) contained inadequate non-clinical data and an incorrect version of a clinical dataset, and (2) consequently the NDA was unlikely to gain approval by the U.S. Food & Drug Administration (“FDA”).

When, on April 8, 2019 Defendants announced the regulator determined that the NDA was not sufficiently complete to permit a substantive review, the price of Zogenix shares fell sharply lower on April 9, 2019.

“We’re focused on investors’ losses, whether Defendants knew that the NDA they submitted on February 5 was not sufficiently complete to permit the FDA to conduct a substantive review, and the extent to which investors may have been misled,” said Hagens Berman partner Reed Kathrein.  


Hagens Berman purchases advertisements on search engines, social media sites and other websites. Transmission of the information contained or available through this website is not intended to create, and receipt does not constitute, an attorney-client relationship. If you seek legal advice or representation by Hagens Berman, you must first enter a formal agreement. All information contained in any transmission is confidential and Hagens Berman agrees to protect information against unauthorized use, publication or disclosure. This site is regulated by the Washington Rules of Professional Conduct.

Back to all cases

Contact:

Please fill out the form below and we will get back to you as soon as we can.
 
Full Name *
Phone *
Email *
Shares Purchased During the Class Period *
Estimated Total Losses *
*Required field
Please list the date, quantity and share price of your purchases/sales during the Class Period so that we can calculate your losses. *
Upload your trade information. *
*
*
*
*
 

Case videos

Case Gallery

Case Timeline

04/15/19: Investigation